Age (years)
|
Sex
|
Onset
|
LOO (days)
|
Subtype
|
CIC
|
CM
|
IVIG
|
AV
|
Recovery
|
Country
|
---|
61
|
f
|
B
|
9
|
AIDP
|
nr
|
No
|
Yes
|
No
|
Yes
|
China
|
65
|
m
|
A
|
9
|
AMSAN
|
nd
|
DM
|
Yes
|
No
|
nr
|
Iran
|
54
|
m
|
A
|
8
|
AIDP
|
nr
|
No
|
Yes
|
Yes
|
Yes
|
USA
|
70
|
f
|
A
|
23
|
AIDP
|
nd
|
No
|
Yes
|
Yes
|
nr
|
Italy
|
66
|
f
|
A
|
7
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Yes
|
Italy
|
54
|
f
|
A
|
21
|
AIDP
|
nd
|
No
|
Yes
|
No
|
Yes
|
Germany
|
70
|
f
|
A
|
3
|
AMSAN
|
No
|
RA
|
Yes
|
No
|
Partial
|
Morocco
|
20
|
m
|
A
|
5
|
AMAN
|
nd
|
No
|
Yes
|
No
|
Yes
|
India
|
71
|
m
|
A
|
4
|
AIDP
|
No
|
AHT, AAR, LC
|
Yes
|
Yes
|
Death
|
Italy
|
64
|
m
|
A
|
11
|
AIDP
|
nd
|
No
|
Yes
|
Yes
|
nr
|
France
|
nr
|
nr
|
A
|
7
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
nr
|
nr
|
A
|
10
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Yes
|
Italy
|
nr
|
nr
|
A
|
10
|
AMAN
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
nr
|
nr
|
A
|
5
|
AMAN
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
nr
|
nr
|
A
|
7
|
AMAN
|
No
|
nr
|
Yes, PE
|
No
|
nr
|
Italy
|
50
|
m
|
A
|
3
|
MFS, PNC
|
No
|
No
|
Yes
|
No
|
Yes
|
Spain
|
39
|
m
|
A
|
3
|
MFS, PNC
|
No
|
No
|
No
|
No
|
Yes
|
Spain
|
61
|
m
|
A
|
10
|
MFS
|
No
|
No
|
S
|
No
|
Yes
|
Spain
|
76
|
f
|
A
|
8
|
GBS (no NCS)
|
nd
|
No
|
No
|
nr
|
Death
|
Spain
|
~ 75
|
m
|
B
|
10
|
AIDP
|
No
|
No
|
Yes
|
No
|
Yes
|
Swiss
|
43
|
m
|
A
|
10
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Yes
|
Spain
|
64
|
m
|
A
|
23
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Yes
|
France
|
72
|
m
|
A
|
7
|
AIDP
|
No
|
AHT, CHD, AL
|
Yes
|
Yes
|
Partial
|
USA
|
~ 65
|
m
|
A
|
17
|
AIDP
|
No
|
No
|
Yes
|
No
|
Yes
|
Italy
|
67
|
f
|
A
|
10
|
nr
|
No
|
Breast cancer
|
PE
|
Yes
|
Partial
|
USA
|
54
|
m
|
A
|
14
|
AIDP
|
nd
|
nr
|
Yes
|
No
|
Partial
|
USA
|
43
|
m
|
A
|
21
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Yes
|
France
|
71
|
f
|
A
|
10
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
France
|
36
|
m
|
A
|
4
|
MFS
|
nr
|
nr
|
Yes
|
No
|
Yes
|
USA
|
55
|
m
|
A
|
20
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
60
|
m
|
A
|
3
|
AMSAN
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
58
|
m
|
AB
|
0
|
AIDP
|
No
|
No
|
Yes
|
No
|
Partial
|
Canada
|
52
|
f
|
A
|
15
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
Swiss
|
63
|
f
|
A
|
7
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Yes
|
Swiss
|
61
|
f
|
A
|
22
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
Swiss
|
53
|
f
|
B
|
nr
|
AIDP
|
No
|
No
|
PE
|
No
|
Partial
|
Turkey
|
51
|
f
|
A
|
14
|
MFS
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Spain
|
56
|
f
|
A
|
15
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Spain
|
68
|
m
|
A
|
14
|
AIDP
|
nr (ASPC)
|
nr
|
Yes, PE
|
Yes
|
Partial
|
Austria
|
55
|
f
|
A
|
14
|
AIDP
|
nr
|
No
|
Yes
|
Yes
|
Partial
|
Spain
|
53
|
m
|
A
|
24
|
AIDP
|
No
|
No
|
Yes
|
No
|
Yes
|
Netherlands
|
57
|
m
|
A
|
6
|
AIDP
|
No
|
AHT, psoriasis
|
Yes
|
Yes
|
Partial
|
UK
|
21
|
m
|
A
|
16
|
AIDP
|
nr
|
AHT, DM
|
PE
|
No
|
Yes
|
USA
|
41
|
m
|
A
|
10
|
AIDP
|
nr
|
DM
|
Yes
|
No
|
Partial
|
Iran
|
38
|
m
|
A
|
16
|
AIDP
|
nr
|
AHT
|
PE
|
No
|
Yes
|
Iran
|
14
|
f
|
A
|
nr
|
GBS
|
nr
|
No
|
Yes
|
No
|
Yes
|
Iran
|
49
|
m
|
A
|
14
|
AIDP
|
No
|
No
|
Yes
|
No
|
Yes
|
UK
|
68
|
m
|
A
|
5
|
AIDP
|
nr
|
AHT, HLP
|
Yes
|
No
|
Yes
|
Italy
|
11
|
m
|
A
|
21
|
AIDP
|
nr
|
No
|
Yes
|
No
|
Yes
|
Saudi
|
15
|
m
|
A
|
nr
|
AMAN
|
No
|
No
|
Yes
|
No
|
Partial
|
Brazil
|
72
|
m
|
A
|
18
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
72
|
m
|
A
|
30
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
49
|
f
|
A
|
14
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
94
|
m
|
A
|
33
|
AIDP
|
nr
|
nr
|
S
|
No
|
Partial
|
Italy
|
76
|
m
|
A
|
22
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
64
|
m
|
A
|
nr
|
GBS?
|
nr
|
DM
|
Yes
|
Yes
|
Yes
|
Japan
|
77
|
m
|
A
|
nr
|
AIDP
|
nr
|
AHT, HLP
|
Yes
|
No
|
Yes
|
Spain
|
58
|
f
|
A
|
6
|
AIDP
|
No
|
nr
|
PE
|
No
|
Yes
|
USA
|
56
|
f
|
A
|
7
|
AIDP
|
No
|
AHT, thyroxin ↓
|
nr
|
nr
|
Partial
|
Germany
|
61
|
f
|
A
|
14
|
AMAN
|
No
|
AHT, HLP
|
PE
|
No
|
Yes
|
USA
|
75
|
m
|
A
|
nr
|
nr
|
No
|
spinal trauma
|
Yes
|
No
|
Yes
|
USA
|
37
|
nr
|
A
|
10
|
nr
|
nr
|
nr
|
nr
|
nr
|
nr
|
Belgium
|
60
|
f
|
A
|
22
|
nr
|
nr
|
Migraine
|
Yes
|
No
|
Partial
|
USA
|
∅57 |
33 m
|
nr
|
0–37
|
nr
|
nr
|
nr
|
Yes, n = 46
|
nr
|
Death, n = 1
|
UK, n = 47
|
| | | | | | |
PE, n = 1
| |
nr, n = 46
| |
51
|
m
|
A
|
12
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Germany
|
34
|
m
|
A
|
4
|
PNC
|
nr
|
Strabism
|
Yes
|
No
|
Partial
|
USA
|
71
|
f
|
A
|
Days
|
PNC
|
nr
|
AHT
|
No
|
No
|
Partial
|
USA
|
65
|
m
|
A
|
3
|
AIDP
|
nr
|
No
|
Yes
|
No
|
Yes
|
Germany
|
74
|
f
|
A
|
nr
|
AIDP
|
No
|
Lymphoma
|
Yes
|
No
|
Yes
|
Spain
|
49
|
m
|
A
|
14
|
MFS
|
No
|
Crohn’s disease
|
Yes
|
Yes
|
partial
|
USA
|
65
|
f
|
A
|
nr
|
AIDP
|
nr
|
Fibromyalgia
|
Yes
|
Yes
|
Death
|
Italy
|
12
|
m
|
A
|
7
|
nr
|
nr
|
No
|
Yes
|
Yes
|
Death
|
Tanzania
|
88
|
f
|
A
|
2
|
AMSAN
|
nr
|
nr
|
PE
|
Yes
|
Partial
|
Iran
|
47
|
m
|
A
|
7
|
AMSAN
|
nr
|
nr
|
PE
|
Yes
|
Death
|
Iran
|
58
|
m
|
A
|
9
|
AMSAN
|
nr
|
nr
|
Yes, PE
|
Yes
|
Death
|
Iran
|
54
|
m
|
A
|
3
|
nr
|
nr
|
GBS, DN
|
Yes
|
No
|
Yes
|
USA
|
57
|
m
|
A
|
nr
|
AMAN
|
nr
|
nr
|
Yes
|
No
|
nr
|
Italy
|
37
|
m
|
A
|
14
|
AIDP
|
nr
|
nr
|
Yes
|
Yes
|
Partial
|
Iran
|
41
|
m
|
A
|
10
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Yes
|
Guinea
|
76
|
m
|
A
|
7
|
AIDP
|
No
|
Cardiomyopathy
|
Yes
|
No
|
Partial
|
France
|
∅59.2 |
22 m
|
A
|
16–35
|
AIDP, n = 23
|
nr
|
Several
|
n = 25
|
n = 5
|
Partial
|
UK, n = 30
|
| | | |
AMAN, n = 2
| | |
PE, n = 2
| | | |
44
|
m
|
A
|
nr
|
nr
|
nr
|
AHT, asthma
|
Yes
|
No
|
Yes
|
USA
|
54
|
f
|
A
|
20
|
AMAN
|
nr
|
Asthma
|
No
|
No
|
Partial
|
Japan
|
55
|
f
|
A
|
11
|
AMSAN
|
nr
|
Lung disease
|
Yes
|
Yes
|
Death
|
Iran
|
8
|
m
|
B
|
nr
|
AIDP
|
No
|
No
|
Yes
|
Yes
|
Partial
|
USA
|
65
|
m
|
A
|
14
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Iran
|
70
|
f
|
A
|
90
|
nr
|
nr
|
RSD
|
Yes
|
No
|
Yes
|
USA
|
55
|
f
|
A
|
10
|
AMAN
|
nr
|
DM, AHT
|
Yes
|
No
|
Partial
|
India
|
72
|
m
|
A
|
6
|
AIDP
|
nr
|
AHT
|
Yes
|
Yes
|
Death
|
India
|
55
|
m
|
A
|
7
|
AMSAN
|
nr
|
DM, AHT, RI
|
Yes
|
No
|
Partial
|
India
|
49
|
m
|
A
|
10
|
AIDP
|
nr
|
DM, AHT
|
Yes
|
No
|
Partial
|
India
|
53
|
m
|
A
|
nr
|
nr
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
36
|
m
|
A
|
18
|
AIDP
|
nr
|
AHT, NTX
|
Yes
|
Yes
|
Partial
|
USA
|
57
|
m
|
A
|
17
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
∅53 |
11 m
|
A
|
0.5–28
|
AIDP
|
No, n = 4
|
nr
|
Yes, n = 15
|
nr
|
Partial,
|
Italy, n = 17
|
| | | | | | |
PE, n = 2
| |
Death, n = 1
| |
54
|
f
|
AB
|
0
|
nr
|
No
|
AHT
|
Yes
|
No
|
Partial
|
Spain
|
58
|
f
|
A
|
14
|
nr
|
nr
|
Disc prolapse
|
Yes
|
No
|
Partial
|
USA
|
65
|
m
|
A
|
nr
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
73
|
m
|
AB
|
0
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
55
|
m
|
A
|
20
|
AIDP/MFS
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
46
|
f
|
A
|
3
|
AIDP
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
60
|
m
|
A
|
20
|
AMSAN
|
No
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
63
|
f
|
A
|
15
|
AMSAN
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
~ 35
|
m
|
A
|
nr
|
AMAN
|
No
|
nr
|
Yes
|
No
|
Partial
|
UK
|
49
|
m
|
A
|
11
|
PCB
|
No
|
AHT, seminoma
|
No
|
No
|
Partial
|
Italy
|
54
|
m
|
A
|
4
|
AIDP
|
nr
|
AHT, obesity
|
Yes
|
Yes
|
Partial
|
Spain
|
54
|
nr
|
nr
|
nr
|
nr
|
No
|
AHT, HLP
|
Yes
|
Yes
|
Yes
|
Spain
|
72
|
f
|
A
|
8
|
AIDP
|
No
|
nr
|
Yes
|
Yes
|
Partial
|
Italy
|
48
|
m
|
A
|
18
|
AIDP
|
nr
|
DM
|
PE
|
No
|
Partial
|
USA
|
46
|
m
|
A
|
18
|
AIDP
|
nr
|
nr
|
No
|
No
|
Partial
|
Iran
|
65
|
m
|
A
|
10
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Iran
|
66
|
f
|
B
|
No symptom
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Italy
|
66
|
f
|
A
|
30
|
AIDP
|
nr
|
DM, AHT, arthritis
|
Yes
|
No
|
Partial
|
Iran
|
55
|
f
|
A
|
31
|
AMSAN
|
nr
|
COPD
|
Yes
|
Yes
|
Death
|
Iran
|
14
|
f
|
A
|
nr
|
nr
|
nr
|
No
|
Yes
|
No
|
Yes
|
Iran
|
38
|
m
|
A
|
16
|
AIDP
|
nr
|
No
|
PE
|
No
|
Partial
|
Iran
|
20-63
|
7 m
|
nr
|
nr
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
UK, n = 7
|
65
|
m
|
A
|
5
|
AIDP
|
nr
|
DM, AHT
|
Yes
|
Yes
|
Death
|
Sudan
|
43
|
m
|
A
|
10
|
AIDP
|
nr
|
nr
|
Yes
|
No
|
Partial
|
Spain
|
63
|
m
|
A
|
1
|
MFS
|
nr
|
nr
|
No
|
No
|
Partial
|
UK
|
61
|
m
|
A
|
nr
|
MFS
|
No
|
nr
|
Yes
|
No
|
Yes
|
Germany
|
58
|
m
|
B
|
nr
|
AIDP
|
nr
|
nr
|
Yes
|
Yes
|
Partial
|
UK
|
70
|
f
|
A
|
15
|
AMAN
|
nr
|
AHTt, obesity
|
Yes, PE
|
No
|
Partial
|
Italy
|
- A, onset of GBS after onset of non-neurological manifestations; AAR Aortic aneurysm repair; AHT Arterial hypertension; AL Alcoholism, ASPC Antibodies for SARS-CoV-2 positive in CSF; AV Artificial ventilation; B, onset of GBS before onset of non-neurological manifestations; CHD Coronary heart disease; CIC CoV2 in CSF; CM Comorbidities; DM Diabetes; f Female; HLP Hyperlipidaemia; LC Lung cancer; LOO Latency between onset of GBS and COVID-19 respectively vice versa; m Male; nd Not done; nr Not reported; NCS Nerve conduction study; NTX Renal transplantation; pc Personal communication; PCB Pharyngeal, cervical, brachial variant of GBS; PE Plasma exchange; PNC Polyneuritis cranialis; RA Rheumatoid arthritis; RI Renal insufficiency; RSD Reflex sympathetic dystrophy; S Steroids